Representative before the EPO

Technology company logo thumb
no operation time available
Technology Company

We have observed 23 EP applications Peter Küng has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after January 17, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12707732

CEA ANTIBODIES

IPC classification:
C07K 16/30
Applicant:
Roche Glycart AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP12717674

NOVEL IMMUNOCONJUGATES

IPC classification:
A61K 39/395, A61K 47/48, C07K 14/54, C07K 14/55, C07K 16/46, C07K 19/00, C12N 15/26
Applicant:
Roche Glycart AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP12750364

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/30
Applicant:
Roche Glycart AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP12748487

ANTI-MCSP ANTIBODIES

IPC classification:
A61P 35/00, C07K 16/18, C07K 16/30
Applicant:
Roche Glycart AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12748693

A METHOD FOR PREDICTING CLINICAL BENEFIT IN THE TREATMENT OF NEURODEVELOPMENTAL, NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS

IPC classification:
G01N 33/68
Applicant:
F. Hoffmann-La Roche AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12758435

PDE10 MODULATORS

IPC classification:
A61K 31/4155, A61K 31/4178, A61K 31/4192, A61K 31/4196, A61K 31/422, A61P 25/00, C07D 231/14, C07D 233/90, C07D 401/14, C07D 403/12, C07D 413/12, C07D 413/14, C07D 417/12, C07D 417/14, C07D 471/04
Applicant:
F. Hoffmann-La Roche AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12759445

TRIAZOLOPYRIDINE COMPOUNDS AS PDE10A INHIBITORS

IPC classification:
A61K 31/437, A61P 25/00, C07D 471/04
Applicant:
F. Hoffmann-La Roche AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
PATENT GRANTED
EP13707176

ABETA ANTIBODY FORMULATION

IPC classification:
A61K 9/00, A61K 39/395, A61K 47/10, A61K 47/18, A61K 47/26
Applicant:
F. Hoffmann-La Roche AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12729457

ANTIBODY BINDING TO ABCA1 POLYPEPTIDE

IPC classification:
C07K 16/18
Applicant:
F. Hoffmann-La Roche AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12728527

A METHOD FOR THE IDENTIFICATION OF BETA-SHEET AGGREGATED PROTEIN LIGANDS

IPC classification:
G01N 33/68
Applicant:
F. Hoffmann-La Roche AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13725360

TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS

IPC classification:
A61K 31/4192, C07D 403/06, C07D 471/04, C07D 487/04
Applicant:
F. Hoffmann-La Roche AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP13727559

PYRROLIDINO HETEROCYCLES

IPC classification:
A61K 31/4162, A61K 31/4196, A61K 31/47, A61K 31/498, A61K 31/517, A61K 31/519, A61P 25/00, C07D 413/04, C07D 471/02, C07D 487/02
Applicant:
F. Hoffmann-La Roche AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP13756076

BLOOD BRAIN BARRIER SHUTTLE

IPC classification:
A61K 39/395, A61P 25/28, C07K 16/18, C07K 16/28, C07K 16/46
Applicant:
F. Hoffmann-La Roche AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP13786468

TRIAZOLO COMPOUNDS

IPC classification:
A61K 31/519, A61P 25/00, C07D 487/04
Applicant:
F. Hoffmann-La Roche AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
PATENT GRANTED
EP14703290

RADIOLABELED COMPOUNDS

IPC classification:
A61K 31/437, A61K 51/04, A61P 9/00, A61P 25/00, A61P 35/00, C07B 59/00, C07D 471/04, G01N 33/60
Applicant:
F. Hoffmann-La Roche AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12702045

MUTANT INTERLEUKIN-2 POLYPEPTIDES

IPC classification:
A61K 39/395, A61K 47/48, C07K 14/55, C12N 15/26
Applicant:
Roche Glycart AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11791543

TRIAZOLOPYRIDINE COMPOUNDS

IPC classification:
A61K 31/437, A61P 3/10, A61P 25/00, A61P 35/00, C07D 471/04, C07D 519/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14747595

THERAPEUTIC FUSION PROTEIN

IPC classification:
A61P 25/28, C07K 9/00, C07K 14/47, C07K 16/18, C07K 16/28, C07K 16/46
Applicant:
F. Hoffmann-La Roche AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP14777091

APPARATUS FOR LEAK DETECTION

IPC classification:
G01M 3/24, G01M 3/32
Applicant:
F. Hoffmann-La Roche AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP14802450

IMIDAZOLE DERIVATIVES

IPC classification:
A61K 45/06, A61P 25/18, C07D 403/14, C07D 487/04
Applicant:
F. Hoffmann-La Roche AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
The patent has been granted
EP15701365

(HETERO)ARYL IMIDAZOLES/PYRAZOLES FOR TREATMENT OF NEUROLOGICAL DISORDERS

IPC classification:
A61K 31/501, A61K 31/519, A61P 25/00, C07D 487/04
Applicant:
F. Hoffmann-La Roche AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP15704558

BLOOD BRAIN BARRIER SHUTTLE

IPC classification:
A61K 38/06, A61K 38/10, A61K 39/395, A61K 47/42, A61P 25/28, C07K 5/08, C07K 7/08, C12N 15/09
Applicant:
F. Hoffmann-La Roche AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP15763330

METHOD FOR MONITORING CATHEPSIN S INHIBITION

IPC classification:
C07K 16/00, C07K 16/28, C12Q 1/37, G01N 33/569, G01N 33/573
Applicant:
F. Hoffmann-La Roche AG
Agent:
Peter Küng, F. Hoffmann-La Roche AG
Status:
Request for examination was made

Please Sign in to use this feature